View all veterinary jobs
VetSurgeon.org publishes a curated feed of veterinary news for practising veterinary surgeons, with a primary focus on the UK profession.
We select stories based on their practical relevance, clinical interest, or professional significance — filtering out noise so busy vets can stay informed quickly.
Our coverage includes:
We report across all areas of practice, including companion animal, farm, equine and exotic species.
Our editorial approach is deliberately selective and concise. We prioritise clarity and relevance over volume, aiming to make each story worth your time.
You can follow VetSurgeon News by subscribing to the daily, weekly or monthly email digest, or via our channels on Facebook and LinkedIn.
230 vets took part in the survey1.
75% reported that they see rabbits affected by dental disease regularly.
GI stasis came in second place at 54%, followed by obesity at 52%.
They were followed by respiratory tract infections (21%) mobility disorders (19%), urinary disease (10%) and pododermatitis (10%).
Purina says the three most common diseases are all intrinsically linked to the feeding of poor-quality diets and despite substantial improvements in nutritional knowledge among rabbit owners, 57% of rabbits are still being fed inappropriately.
Claire Hamblion, Supreme’s Marketing Director said: “Owners want to do the right thing, but all too often lack of awareness about nutrition leads to poor health and wellbeing.
"The great news is that progress is being made.
"Well over half of UK rabbit owners now take their pet to the vet at least once a year2, and 79% of vets say that nutritional knowledge among rabbit owners has significantly improved.
"We’re keen to build on this and are proud to offer not just high-quality species-specific nutrition but a range of educational materials as well as free samples to help veterinary teams engage with owners”.
References
RSA Insurance Group, which underwrites pet insurance on behalf of MORE TH>N, Tesco Bank, M&S, John Lewis, Argos and Homebase, has clarified recently announced changes to its policy conditions concerning cases which need to be referred for specialist treatment.
In a letter dated 22nd May, which was sent to practices in the Midlands and the NW, the company said:
"With effect from the 25th May 2015, if you need to refer a pet under any of the above Brands to a specialist or referral vet, and the visit is not in response to an emergency, then our customer / your Client can contact us on the relevant number below before any appointment is made. We will then agree which of our preferred specialist or referral practices our customer should go to, dependant (sic) on the individual circumstance relating to the claim. If our customer does not get in touch with us or we have not agreed to the visit, then this could result in our customer suffering a financial impact. This amount will be in addition to the policy excess."
Speaking to VetSurgeon.org, Keith Maxwell, Head of Pet Claims at RSA said: "What we're saying to the primary practices is that we want to speak to our customers before they go to a referral vet. We want to engage with our customers to let them know that we have referral vets who we are starting to work with across those specific regions. We are not saying to customers that you have to use those referral vets and if you don't, we won't provide cover."
This appeared to contradict a statement that a member of VetSurgeon.org had received from John Lewis earlier which said: “If you decided to go to a specialist that wasn’t approved by us, we wouldn’t cover the costs." Keith said: "That is not correct."
Clarifying the financial impact referred to in the company's letter to veterinary practices, Keith said: "In terms of any sort of financial impact on the customer, if we think about the level of benefit that a customer will have under their insurance policy, they will have a maximum cash benefit. If a customer goes to one specific referral vet and the cost of treatment is extremely high, and they have a choice of going to a referral vet that we have been interacting with to get a like for like treatment, the cost will be lower, the financial impact on the customer will be that the overall benefit available to them will be eroded at a faster rate."
He added: "The other thing I would say is that certain customers under our policies will have a policy excess which will be on a percentage basis. Now if you think about a higher cost treatment which will incur a percentage excess, it will be a higher amount the customer will have to pay, as opposed to going to a referral vet where they can get the exact same high quality treatment, but the overall cost will be lower; they will pay a lower excess. So we are not saying we are going to penalise a customer. There are other financial consequences i.e. eroding benefit or having to pay a greater amount of excess."
Whilst RSA appears not to be removing the freedom of choice over referrals, there remains the potential for a conflict of interest when a primary practitioner recommends treatment at a centre they believe to be the most suitable for the case, and the client then rings the insurer only to be advised to use an alternative, primarily for reasons of cost. Keith said: "What I would say is that we are at the start of a journey. We've selected a small part of the country. We are very much in a 'test and learn' phase. As we have selected referral vets, we have gone through obviously quite a lengthy process of engaging with referral vets, looking at specialism, looking at their accreditation, looking at their capability, their skill, equipment within their practices, what their areas of specialism are, so we are building up this view. It does come down to we want to learn from this. We want to engage with our customers. We want to offer our customers choice. We want to make sure that our customers will not be receiving an inferior service or inferior treatment or level of specialism in any specific way."
VetSurgeon.org asked how RSA has selected its preferred referral practices, and how others can join its network. Keith said: "When we started this journey, we made contact with a significant number of referral vets across the country. Some referral vets just said point blank 'No, we don't want to talk to you'. Others said 'Yes, we'd like to come and have some discussions'. So we took those forward and then we took the referral vets through a benchmarking process based on a full list of criteria, and within RSA we have veterinary expertise helping us along that journey, so we're not just doing this on our own. We are very much an open door to interacting and liaising with referral vets."
Keith concluded by saying: "We are focused on our customers here. We are focused on making sure that pet insurance is sustainable in the long term, both for our customers and for vets across the country."
Bravecto Plus contains fluralaner (280 mg/ml), an ectoparasiticide which provides systemic activity against ticks (lxodes ricinus) and fleas (Ctenocephalides felis), and moxidectin (14 mg/ml), an endoparasiticide which provides systemic activity against a range of internal worms, including heartworm (Dirofilaria immitis), intestinal roundworm and hookworm.
Bravecto Plus is applied topically using the "Twist'n'Use" pipette. Once applied, the product kills ticks and fleas for 12 weeks, while also treating intestinal roundworm and hookworm and preventing heartworm disease for eight weeks.
Bravecto Plus can also be used as part of a treatment strategy for flea allergy dermatitis.
Bravecto was first launched in 2014 as a chewable tablet for dogs. In 2016 Bravecto spot-on was launched as a topical solution for dogs and cats. More than 80 million doses of Bravecto have been sold in 72 countries since 2014.
Amanda Melvin, marketing manager, at MSD Animal Health, said: "We are pleased to introduce the latest innovation in feline parasite protection to the Bravecto family."
For more information, refer to the summary of product characteristics or contact your MSD account manager.
Ms Bowler faced four sets of charges, each of which contained sub-charges, summarised as follows:
Despite being served with the Notice of Inquiry, Ms Bowler decided not to attend the hearing due to ill-health but was represented by a counsel and solicitors.
The Committee did not find that Ms Bowler was medically unfit to attend on the basis of the medical evidence before it.
The Committee also concluded that it was in the public interest and interests of Ms Bowler to proceed with the hearing in her absence so that it could be concluded in a timely manner.
Ms Bowler’s counsel applied for parts of the hearing to be heard in private on health grounds, which was approved by the Committee.
It was also determined that any parts in the Committee’s decision or hearing that referred to Ms Bowler’s health would be redacted.
At the outset of the hearing, Ms Bowler’s counsel made admissions to five of the sub-charges which the Committee therefore found proven.
She also made some partial admissions in relations to a further 11 sub-charges.
After hearing a wide range of evidence, both written and oral, from Ms Bowler, the College, from clients and from an expert witness, the Committee found all charges proved except for four sub-charges.
On deciding whether the proved charges amounted to serious professional misconduct, the Committee took the following aggravating factors into account.
In mitigation:
In all, the Committee decided that the seriousness of the misconduct meant that a sanction was necessary to meet the public interest.
When deciding on whether to issue a reprimand with or without a warning, the Committee once again decided that the misconduct was too serious to allow for this.
It also decided that a reprimand and/or warning was not sufficient to protect animals and the wider public interest.
It then went onto consider whether a sanction of ‘suspension’ was sufficient but noted that it did not have enough evidence to show that Ms Bowler had shown significant insight to continue to practise unrestricted in the future.
The Committee eventually concluded that Ms Bowler’s conduct was incompatible with remaining on the Register.
Neil Slater, chairing the Disciplinary Committee and speaking on its behalf, said: “The Committee decided that the broad range of Ms Bowler’s misconduct which had spanned three years and eight months and involving injury or risk of injury to 18 animals, was incompatible with remaining on the Register and the public interest required removal from the Register even when all of Ms Bowler’s mitigation was taken into account.
“The Committee decided that it did not have sufficient evidence overall on Ms Bowler’s insight, current competence and future risk to persuade it that the lesser sanction of suspension was appropriate in this case.
“Although Ms Bowler had shown some insight, the Committee decided that she would need to have provided detailed evidence about her current practice before it could decide that she no longer represented a risk to animals in the future.
“The Committee therefore concluded that ‘removal from the Register’ was the appropriate and proportionate sanction because there had been a serious departure from professional standards, a reckless disregard for professional standards, multiple cases involving harm or risk of harm to animals and because, in Ms Bowler’s absence, it had been difficult to unravel whether she had an attitudinal problem.
“These were all factors in the Disciplinary Committee Sanctions Guidance that indicated that a sanction of removal was the appropriate sanction and, in the Committee’s decision, removal from the Register was the only sanction which would meet the public interest.
"It concluded that a lesser sanction would undermine public confidence in the profession and in the regulatory process.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
NexGard Combo is a systemic isoxazoline-based endectocide designed specifically for cats which contains esafoxolaner, eprinomectin and praziquantel.
The new product provides one month’s protection against fleas and five week's protection against the most common tick on cats, Ixodes ricinus. It also treats the roundworms, Toxocara cati and Toxascaris leonina, hookworms, tapeworms and ear mites, against the last of which Nexgard Combo provides 97.2 to 99.9% efficacy following one treatment1.
NexGard Combo can be used in kittens from eight weeks of age and 0.8 kg in weight, making it suitable for most kittens at first vaccination. It is available in two pack sizes: small, for kittens weighing 0.8 - 2.5kg and large, for adult cats weighing 2.5 - 7.5kg. For cats weighing 7.5kg or over, an appropriate combination of applicators should be used.
Jackie Sterratt, senior brand manager at Boehringer Ingelheim, said: “We’re excited to add to the successful NexGard range and to help vets treat more cats. We know only one in two cats is treated for fleas2 and cats are only wormed on average three times per year3 despite all cats being at risk of fleas and most cats requiring monthly roundworming treatment2, 3, so there is a big opportunity to increase treatment rates and compliance. As the only product on the market to treat fleas, ticks, ear mites, roundworms and tapeworms, NexGard Combo offers a simple solution for cats at risk of multiple parasites."
To support the launch Boehringer has produced a marketing package which includes a kitten support pack, client leaflets, dispensing envelope and parasite risk checker.
For further information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).
Filavac is licensed for use in rabbits within the UK and provides 12 month's duration of immunity, allowing it to fit into annual vaccination and healthcare plans.
Filavac can be administered from 10 weeks of age with a seven-day onset of immunity. It is presented in 5 x 0.5ml single dose packs.
Nicki Glen, marketing project manager for Filavac at Ceva Animal Health said: "Rabbits are increasingly popular as household pets and should therefore become an important focus for veterinary practices.
"We are delighted to have taken on the exclusive distribution of Filavac to provide veterinary practices with a competitively-priced and convenient vaccination for both RHDV 1 and 2."
For further information, contact your local Ceva Animal Health territory.
The VMD's ruling sets a chilling precedent for the curtailment of free speech by a Government body.
The ruling came to light after VetSurgeon.org published an independent video news report relating to the launch of Bravecto Injectable, a new yearly flea treatment for dogs.
The film was neither paid for nor commissioned by the manufacturer, and nor did the maker exercise editorial control over its content.
The film was clearly labelled for and aimed at veterinary professionals, and its intent was not to promote the sale or supply of a prescription medicine, but rather to inform vets and nurses about the new product, albeit in an enthusiastic manner.
It was therefore not an advertisement, but journalism.
The Dictatorship nevertheless argued that it defines any social media content that mentions the brand name of a prescription veterinary medicine and which does not give a balanced overview of all the other treatment options for a given condition, as an advertisement.
This, it said, is regardless of whether content is created by the manufacturer or supplier of drug to promote sales of their product, or any member of the public or journalist who just wants to talk about or report on a prescription medicine publicly without any intent to promote sales.
The Dictatorship's position is that any such content can only appear in spaces dedicated to the appropriate audiences.
Notwithstanding the fact that all of VetSurgeon.org's social media channels are dedicated to the appropriate audiences, it leaves us in the almost laughable position where, according to the VMD, the BBC is allowed to report about powerful prescription medicines for humans in a way that inevitably promotes their supply, but VetSurgeon.org cannot report the launch of ... wait for it ... a flea treatment.
However the VMD then shared its incontinent interpretation of the law in a series of emails in which it was unable to provide a consistent definition of where it would allow content about prescription veterinary medicines to be published.
It first claimed (without any supporting evidence of any law to this effect), that:
"... it would need to be on a closed page which only followers could view would require active confirmation of the follower’s professional status before allowing access."
However, it swiftly backtracked, presumably realising that this definition would require Vet Times to remove most of its content from public view, including actual advertisements for veterinary prescription medicines published by the manufacturer.
When pressed, the VMD changed tack to a rather looser definition:
"Regulation 11(3) of the VMR does allow you to advertise POM-V products at vets and vet nurses, however to ensure this wouldn’t also be considered as advertising to the general public, it would need to be in a closed space, separate from the general public and directed at veterinary healthcare professionals. For example, on a website, or closed social media group."
However, it then presumably realised that Vet Times would still have to remove most of its content because it is not a closed space, and loosened its definition further still.
"Please note that, where an advertisement for POM-V or POM-VPS veterinary medicine appears in a space dedicated to the appropriate audiences this would not be a breach of Regulation 11(1)(a) due to Regulation 11(3) and Regulation 11(5)."
Clearly the Dictatorship was making it up as it went along.
Nevertheless, it threatened VetSurgeon.org that it would contact TikTok and demand removal of the film.
So what does this matter?
Two reasons.
Firstly, it may just be a report about a flea treatment, but there is an important principle at stake here: it is simply not acceptable for the Government to censor free speech about medicines by journalists or members of the public.
This, you would think, is so blatantly obvious that it calls into question the overall competence of the Veterinary Medicines Directorate.
Secondly, the ruling also demonstrates the VMD's backward-looking, Canute-like view of the world we now live in.
People talk and social media is awash with information about prescription veterinary medicines; just try typing 'Bravecto Injectable' into TikTok.
As we all know much of what you find online is false.
Fighting misinformation online is an unwinnable fight.
So perhaps instead, the VMD should promote the dissemination of accurate information in order to counter the misinformation.
Bear in mind, it is only the VMD's interpretation of the law which dictates that a manufacturer cannot publish information which mentions a brand name or give a balanced overview of all treatment options because it would promote the supply or prescription of a veterinary medicine.
It could equally well be argued that manufacturers publishing strictly factual information, ie devoid of hyperbole, would NOT be intended to promote the supply or prescription, but instead to counter false information and provide owners with information which time-poor vets are not always able to.
That would be a more pragmatic approach which would do far more good than trying to censor independent journalists and the public.
Mr Garcia had pleaded guilty of harassment at Nottingham Magistrates Court last September and was sentenced to six weeks’ imprisonment, suspended for 12 months. The magistrates also imposed a restraining order and ordered Mr Garcia to pay compensation and costs as well as a surcharge to fund victim services.
The harassment conviction related to incidents between 30 September 2016 and 27 December 2016 in which Mr Garcia engaged in conduct that amounted to harassment towards a woman including sending offensive text messages, visiting her place of work, attempting to contact her through social media, going to her home address and driving past her home address.
At the outset of the disciplinary hearing Mr Garcia admitted the College's charge against him and that his conviction rendered him unfit to practise veterinary surgery.
Following cross-examination of Mr Garcia on the facts of the case and having considered representation from his counsel, the Disciplinary Committee found that Mr Garcia’s conduct leading to conviction and the conviction itself rendered him unfit to practise as a veterinary surgeon.
Mehmuda Mian, chairing the Committee and speaking on its behalf, said: "It was a serious conviction as demonstrated by the sentence imposed and by the nature of the harassment. It brought distress on [the victim] and will have damaged the reputation of the veterinary profession. The respondent was right to accept that this was the case."
Turning to the sanction for Mr Garcia the Committee considered a number of aggravating factors in his case including the distress caused to the victim as some of the text messages could be interpreted as threats to harm; the fact that Mr Garcia had continued to contact the victim after receiving a warning from the police; the fact he visited her place of work; that there was a sexual element to some of the messages he sent to the victim; and that the pattern of behaviour was sustained over three months and only ended with his arrest. It also considered that his behaviour was contrary to the Code of Professional Conduct and its supporting guidance’s advice on professional and appropriate use of social media.
The Committee also considered mitigating factors such as the fact that, during the period of his conduct, there was a family illness and bereavement; that he admitted the charges before the magistrates and the Committee; that ‘social ineptitude’ was a factor and that he did not recognise the rejection he received from the victim; testimonials as to his capabilities as a veterinary surgeon; and insight into his behaviour as well as taking steps to avoid its repetition.
Ms Mian concluded: "The Committee has determined to suspend the respondent’s registration for a period of five months. This sanction reflects the seriousness of the conviction and the concerns expressed by the Committee in this determination. It will send a message to the respondent and to the profession that conduct such as this is unacceptable. It will afford an opportunity to the respondent to reflect further on his behaviour."
Mr Garcia will have 28 days from the end of the hearing to appeal against the Committee’s decision.
The Committee’s full findings and decision are available at: www.rcvs.org.uk/disciplinary
The RCVS Disclipinary Committee has severely reprimanded and warned as to her future conduct a Brighton-based veterinary surgeon who failed to maintain a proper boundary between her professional and personal relationships with a client.
The eight charges considered at the seven-day hearing involved Marie-Louise Schlemm's treatment of Ratszy, a 16-year old Jack Russell with chronic renal failure, and her relationship with the dog's owner, Ms B, who suffers from mental illness, during May 2010. At that time, Ms Schlemm was employed by Coastway Veterinary Group in Brighton to work for its out-of-hours veterinary services, Vetcall, to which Ratszy had been referred by the PDSA.
The College alleged that Ms Schlemm deliberately misled Ms B as to the condition and prognosis of Ratszy, removed the dog without Ms B's consent, and behaved unprofessionally and inappropriately in her dealings with Ms B. Other allegations were that that she had suggested Ms B tell the PDSA a fabricated story in order that she might see the dog again; made an offer that Ms B and Ratszy could come and stay with her at her home; required Ms B to attend a supermarket car park at 12.30am to collect Ratszy; and took money from Ms B other than for the purposes of legitimate veterinary treatment.
The Committee found both Ms Schlemm and Ms B to be truthful and honest witnesses, and that Ms B's recollection was given to the best of her ability. However, where recollections differed, it relied on contemporaneously prepared clinical records to find that Ms Schlemm did not mislead Ms B to the effect that the dog was not dying. Although recognising that Ms Schlemm's actions were misguided the Committee found that the dog was not taken without consent.
Furthermore, the Committee said in making the offer that Ms B and Ratszy might come and stay with her, Ms Schlemm was wholly misguided and had blurred the distinction between personal and professional activities. By this time, she was aware Ms B suffered from mental illness and so should have allowed the mental health services to take control of the situation. Similarly, she should not have required Ms B to meet in a car park to collect Ratszy, behaviour the Committee described as bizarre and which had compromised Ratszy's welfare. Although the Committee gave Ms Schlemm the benefit of the doubt as to whether money taken was, in fact, to pay for alternative therapy for Ms B, she did not deal with the matter openly and it was a clear breach of trust to both Ms B and Vetcall.
In mitigation, the Committee was satisfied that Ms Schlemm now had a genuine insight into her lack of judgement in her relationship with Ms B, had reflected on the decision of the Committee and fully accepted the "utter stupidity" of her actions. She had also attended courses on teamwork and managing client relationships, and had established good working relationships in a new practice.
Professor Peter Lees, chairing and speaking on behalf of the Committee said: "While the Committee has accepted that Ms Schlemm was motivated by good intentions towards Ms B and Ratszy, she breached the trust of both of Ms B and Vetcall in the way in which she behaved [and] acted in a misguided way in dealing with a vulnerable client, who was suffering from mental illness. In light of the serious nature of its findings, the Committee does not consider it appropriate to take no further action. The Committee has concluded that Ms Schlemm should be severely reprimanded for her conduct and given a warning as to her future conduct [and] reminds the profession of the importance of maintaining a proper boundary between the professional and personal relationships of client and veterinary surgeon."
The company says it will be introducing a UK-specific brand in the coming months, but that each practice will retain its independence and culture.
Ben (pictured) started his career in clinical practice but has spent the past decade building and leading organisations across the veterinary and dental sectors, including laboratory services.
Ben Hanning said: “Veterinary professionals are under more pressure than ever – and I’ve lived that reality.
"Vetopia’s UK launch is about creating a new way forward: empowering vets to focus on exceptional care while giving them the support, resources and ownership opportunities that they deserve.
“Our approach is designed to provide the right balance between autonomy and collaboration.
"Together, we can nurture what makes each clinic special while ensuring every team has the tools to thrive.”
A point of difference which Vetopia says sets it apart is its ownership model, through which more than half of the company’s shares are owned by employees.
This enables vets and clinic leaders to benefit directly from the group’s success, while fostering long-term value, collective commitment and a sense of shared purpose across the network.
Peter Thomsen, Group CEO at Vetopia, said: “Vetopia’s success across Europe shows that veterinary excellence thrives when clinicians lead the way.
"Our country-led model combines local decision-making with the benefits of being part of a larger network, giving practices the freedom to deliver care their way while accessing shared expertise, investment and resources.
www.vetopia.com
Atilla was presented with the concerned owners of an eight year old Staffie at the end of August this year, having found blood in the dog’s urine. He said: "Fortunately the owners were extremely vigilant and noticed the blood. They phoned on a Sunday and arrived in the surgery as an emergency two hours later, bringing with them a urine sample. The urine was dark red and remained so when spun. I then carried out an in-house peripheral blood smear and found the Babesia piroplasms. Treatment started immediately with Imizol injections."
"Having just seen the dog two weeks later for its second injection, the lucky Staffie is thankfully doing very well. This dog was fortunate though as we were not seeing it regularly at the practice so it had not been receiving regular tick treatment. This meant it was exposed to the dangers of tick-borne diseases even though it hadn’t travelled outside the UK."
Hannah Newbury, Technical Manager at MSD Animal Health said: "This case is a reminder of the value of vets remaining vigilant to the possibility of Babesiosis being present in dogs that have not travelled outside the UK or had contact with dogs that have.
"It also highlights the need for vets to discuss parasite risk with owners to ensure that dogs are given regular tick-treatments throughout the year to reduce the risks to pets and owners.”
"As we learnt from the cases of canine Babesiosis in Essex last year, there are established populations of the tick Dermacentor reticulatus acting as vectors of the introduced pathogen Babesia which is a major concern for animal health. It also demonstrates the potential dangers from the inadvertent introduction of novel disease pathogens if vigilance and surveillance are not maintained."
The RCVS Disciplinary Committee has suspended two veterinary surgeons from the Register after finding them guilty of lying to clients and the College about the circumstances of a castration procedure which led to the death of a dog.
The Committee suspended Mr Mpho Donald Lesolle and Mr Georgi Cheshmedzhiev from the Register for four and two months respectively, following surgery undertaken on Benson, a two-year-old male Labradoodle belonging to Mr and Mrs Grayson.
During the proceedings, the Committee heard that, on 6 August 2013, Mr and Mrs Grayson brought Benson to the Swinfen Veterinary Centre in Stafford, where Mr Lesolle is the practice principal and Mr Cheshmedzhiev was his assistant, for the operation which was undertaken by Mr Cheshmedzhiev. Mr Lesolle did not directly supervise the procedure telling the Committee that he was confident that his colleague could carry out the castration, having permitted him to do so on previous occasions.
The Committee heard that, after the operation, a nursing assistant, Ms Bell, had noticed that there was blood on the bedding and that Benson had a swollen scrotum. Mr Lesolle then performed a scrotal ablation on Benson, who was discharged later that day.
However, on the morning of 8 August 2013, Mrs Grayson discovered that Benson had died during the night. An independent post-mortem concluded that he had probably died of intra-abdominal bleeding which caused circulatory collapse. Mr and Mrs Grayson raised a concern with the RCVS in September 2013.
The charge against Mr Lesolle relates to his actions following the operations and during the investigation. The four parts of the charge were that he failed to be sufficiently open with Mr and Mrs Grayson on the circumstances of Benson’s surgery; that, in September 2013, he wrote to the College indicating that he had in fact performed the castration and failing to state that there had been two operations; that, on 23 January 2014, he informed Pam Mosedale, a Veterinary Investigator employed by the College, that he had carried out both procedures; and that, on the same day, he also encouraged his veterinary nursing assistant Ms Bell to be dishonest with the College’s investigators.
Mr Lesolle, who was present at the hearing, admitted all parts of the charge against him. He told the Committee that he decided to take responsibility for Mr Cheshmedzhiev’s operation out of a desire to protect his colleague whom he regarded as vulnerable and lacking in self-confidence. He also accepted that he had encouraged Ms Bell to lie during her interview. He told the Committee that he had persisted with the deceit until 15 January 2015, when he gave a full account of what had occurred.
The three parts of the charge against Mr Cheshmedzhiev, who was not in attendance or represented at the hearing, were that in a letter to the College sent in September 2013, he indicated that he had not undertaken the castration procedure on Benson; that on 23 January 2014 he had denied carrying out the operation while being interviewed by Pam Mosedale; and that, on 19 June 2014, while being interviewed by a solicitor instructed by the College, he said that Mr Lesolle had carried out both procedures.
The Committee found the charge against Mr Lesolle amounted to serious professional misconduct, falling far short of what is expected of a professional. The Committee highlighted the protracted nature of his deceit and the fact that he encouraged another member of staff to participate in it. However, it did accept that his motivation was to protect Mr Cheshmedzhiev.
In deciding on the sanction for Mr Lesolle, the Committee considered the aggravating and mitigating factors. Ian Green, chairing the Committee and speaking on its behalf, said: “Having taken the calculated decision to deceive the College as to what had occurred, he abused his position of responsibility to obtain support for his deceit by involving a junior employee, without any proper consideration of the effect of that decision upon her. Instead he continued with the deceit until he was presented with incontrovertible evidence that he had not carried out both procedures on the dog. In the Committee’s view he showed a wilful disregard for the College’s investigatory process.”
However, in mitigation, it also accepted that he was protecting a colleague and that there was no financial gain. It also considered his personal circumstances, the fact that he is sole principal of a small mixed practice which provides his sole source of income and that the rented accommodation also provides a home for his wife and two children. Taking all factors into account, the Committee imposed a sanction upon Mr Lesolle of four months’ suspension from the Register.
In regards to Mr Cheshmedzhiev, the Committee did not find the part of his charge relating to the letter sent in September 2013 to be proven but, in respect of the other two parts of his charge, found that his conduct fell far short of what is expected of a professional. It highlighted his willing participation in the deceit over a protracted period and his failure to take responsibility for his own involvement in the operation on Benson.
In deciding the sanction, the Committee said that the fact that Mr Cheshmedzhiev had lied to the College’s investigators on two occasions and did not admit that he had carried out the castration and apologise for his actions until February 2015, after he had returned to his native Bulgaria, was an aggravating factor.
Ian Green added: “The Committee accepts that he allowed himself to be persuaded by Mr Lesolle to provide a dishonest account of what had taken place to the College’s investigator Mrs Mosedale, and solicitor, Mr Hudson. It also accepts that he has been described by Mr Lesolle as a vulnerable person, lacking in self-confidence in his ability to practise as a veterinary surgeon in the United Kingdom.
“Nevertheless, Mr Cheshmedzhiev accepted the obligations contained in the Code of Professional Conduct when he registered as an MRCVS, which included an obligation to cooperate honestly with the College’s investigatory process. It has also noted that he has expressed a present intention not to work in or visit the United Kingdom again.”
Taking into account all factors, the Committee decided the appropriate sanction was to suspend him from the Register for two months.
Cladaxxa is a combined amoxicillin/clavulanic antibiotic, which Krka says is bioequivalent to the market reference product1,2,3,4.
The new product is available in three strengths of flavoured tablet, with the 200/50 mg formulation also licensed for cats.
Cladaxxa is presented in blister packaging to protect the clavulanic acid, which is highly sensitive to moisture.
The tablets are ready-scored to help with accurate dosing and halved tablets can be returned to the protective blister packaging to be used within the following 24 hours.
Cladaxxa comes in packs of 60 or 100 tablets.
Krka’s National Sales Manager Will Ridgway, said: "Treating bacterial infections is an important everyday task for vets in practice.
"Cladaxxa is a great example of Krka using its expertise in end to end product design to deliver efficacy and value to our customers.”
Rosemullion Veterinary Practice is a three-site small animal practice owned by CVS.
It has 100 members of staff and dispenses 3,584 medications in an average month.
According to an article in Companion Animal, medication errors account for 30% of all reported errors in veterinary practice1.
Errors can be prescribing errors - where the vet prescribes the incorrect medication or dosage, or dispensing errors where the incorrect medication, strength or volume is dispensed by the pharmacy team.
Some errors can ‘look or sound alike’ – where medications have similar names or packaging – making them easy to mix up.
Rosemullion conducted an initial clinical audit of entries on its VetSafe system between 1st March and 31st May 2023.
Analysis was conducted on the drugs involved, whether they were prescribing or dispensing errors or near misses, and looking for patterns of behaviour or the drugs involved.
During this time there were 29 (0.27%) near misses and 14 (0.13%) errors.
Prescribing near misses most often involved flea and worm products.
Here additional feedback from vets was that it was difficult to remember weight brackets for all products and when weight brackets were included in the drug description this made them easier to prescribe accurately.
As a consequence, the Rosemullion pharmacy team introduced the inclusion of weight brackets on all flea and worm products.
Dispensing errors and near misses were mostly related to ‘look or sound alike’, particularly in worming tablets, flea treatments and Rheumocam cat and dog.
To address this, the Rosemullion pharmacy team added extra labelling to dispensary draws and separated draws for flea and worm treatments into different weight brackets.
Rheumocam – with its similar packaging design and box sizes – was also split into separate cat and dog drawers, and drawers clearly labelled up with the version and volume to make dispensing clearer.
Feedback was also given to the drug manufacturer.
Rosemullion also held a CPD session to highlight the common errors that were occurring, to explain resulting process and systems improvements, and ask the team to take extra care with these dispensaries.
A new ‘handing out medication’ process was also created – involving checking the medication in the bag matched the on the screen notes, confirming it was for the correct animal and validating it was what the owner was expecting.
A subsequent audit was run from 1st October to 31st November 2023.
The results revealed there were no prescribing or dispensing errors (0%) and only 8 (0.13%) near misses during this time.
Alice Bell, Senior Vet and Quality Improvement Lead at Rosemullion Veterinary Practice, said: “We place patient safety at the forefront of all we do.
"We wanted to conduct this extensive audit to assess our prescribing and dispensing processes and systems.
“The methods we had in place made it easy to do the task correctly and the changes we have now put in place have made the process even safer for our clients.
"Our overall error and near miss is now at a really low number compared to our total number of medication dispenses.
“The teams have been very receptive to the improvements and the project has had a positive impact on various aspects of the practice, including on team wellbeing.”
Rosemullion Veterinary Practice’s initiative has recently been recognised with a RCVS Knowledge Highly Commended status at its 2024 awards.
Reference
Bob Martin, maker of the eponymous flea treatment for cats and dogs, has announced that it will be removing the last of its permethrin-containing on-animal flea treatments from sale in supermarkets.
The company says the decision was made following a passionate outpouring of emotion - particularly online - over the large number of unnecessary deaths of cats which have been wrongly treated with permethrin-based products for dogs.
Permethrin poisoning is one of the most commonly reported poisonings in cats worldwide. According to the company, a study carried out by the Feline Advisory Bureau and the Veterinary Poisons Information Service found that 97% of permethrin poisonings in cats have followed the application of a permethrin-containing dog-specific spot on product.
Bob Martin says it believes that most permethrin poisonings are down to mistakes at point of purchase with pet owners mixing up cat and dog products, or being unaware that you cannot use a dog treatment on a cat. For this reason, the company withdrew permethrin from its dog spot ons in 2012, replacing it with fipronil.
Nevertheless, the company continued to sell cat flea collars containing permethrin, which had become indelibly associated with the deaths seen as a result of misusing the dog spot-on.
Georgina Martin, Marketing Manager and great granddaughter of founder Bob Martin said: "Animal health is Bob Martin's top priority. We have decided to reclassify our permethrin-containing on-animal flea treatments to pharmacy-only and call for a change in licensing by the Veterinary Medicines Directorate so that they may only be purchased if advice is given about their correct use.
"This is the next step in our journey as a responsible business having already voluntarily withdrawn permethrin Dog Spot-ons a few years ago which we replaced with fipronil, the same active as used in leading spot on treatments from the vet. To ensure our customers are still able to buy a flea collar from their supermarket we will be launching a new pesticide free flea repellent collar."
Nigel Grimes, Pet Food Buyer at Morrisons PLC said: "It is important for us that our customers who own animals receive the verbal advice and reassurance on the use of permethrin-containing on-animal products. We feel that this advice is needed at the point of sale and should be provided by a suitably qualified person in a pharmacy setting. We will continue to provide pet owners with on-shelf access to a choice of affordable healthcare for their animals from the Bob Martin range."
Meanwhile, Bob Martin has launched the new 'Clear' range of animal collars, which contains margosa extract from neem oil. The company says this natural ingredient is frequently used as an alternative to synthetic insecticides, and is proven to be a highly effective flea repellent, ideal for indoor cats. The new range is now on sale, with the old product being phased out as existing stocks are sold.
The British Association of Homeopathic Veterinary Surgeons is claiming that: "owners can now be confident homeopathic medicines can be effective for common canine and feline conditions in many animals, following a recently published clinical study."
In what the BAHVS says was the largest-ever study of its type, the Clinical Outcomes survey has identified a number of clinical conditions in dogs and cats that homeopathic veterinary surgeons believe may be promising targets for future research in veterinary homeopathy.
In the study, twenty-one homeopathic vets in the UK recorded data from their patients over a 12-month period, and collected information from a total of 1500 dogs and 400 cats. The most frequently treated feline conditions overall were dermatitis, renal failure, overgrooming, arthritis and hyperthyroidism. The most commonly recorded canine conditions were dermatitis, arthritis, pyoderma, colitis and fear. By owners' assessments, a moderate or major improvement was reported overall for 68% of dogs and 63% of cats.
The authors of the study concluded that a programme of controlled research in homeopathy for frequently-treated feline and canine conditions is clearly indicated.
John Alborough, co-publisher of VetSurgeon.org said: "I also find that if I shove toenail clippings up my bottom, it totally cures my indigestion."
ReferenceMathie RT, Baitson ES, Hansen L, Elliott MF, Hoare J. Homeopathic prescribing for chronic conditions in feline and canine veterinary practice. Homeopathy 2010; 99: 243-248.
Mrs Grecko faced two charges.
The first was that she got a nurse colleague to order griseofulvin, a prescription-only antifungal medication, knowing that it was for human use, rather than legitimate veterinary use.
It was also alleged that she then caused a student veterinary nurse to record the order in the name of another veterinary surgeon, who was not involved in the order or prescription of the medication, and falsely record that it was for Mrs Grecko’s dog.
The second charge was that she had acted dishonestly and misleadingly, as the medication was, in fact, intended for use by her husband.
At the outset of the hearing, Mrs Grecko admitted she had asked her RVN colleague to order the medication and for her SVN colleague to record that the medication was for her dog and that doing this was dishonest and misleading.
Mrs Grecko accepted that these admitted charges amounted to serious professional misconduct.
She denied asking an SVN to record it under the name of another veterinary surgeon.
However, the Committee heard from two eye-witnesses who testified consistently that Mrs Grecko had told her SVN colleague to record the medication under another vet's name, and from another witness who testified that Mrs Grecko had made a similar admission.
It therefore found it proven that she had asked her SVN colleague to make a false record, that it was dishonest and misleading, and that together, the charges amounted to serious professional misconduct.
Paul Morris, chairing the Committee and speaking on its behalf said: “The Committee considered that Mrs Grecko’s conduct had breached her obligations as a veterinary surgeon to respect the proper protections that were in place for the control of prescription-only medications.
"She had committed a serious abuse of her position in using the fact that she could obtain medications by virtue of her profession to circumvent the protections.
"She had been prepared to involve others in the course of the conduct.
"In addition, Mrs Grecko had been prepared to engage in an attempt to conceal her actions and falsify the clinical records in the process.
“Although it was acknowledged that Mrs Grecko may have been subject to some conflicting demands, being affected by her husband’s interests and may have felt a pressure to act, the Committee considered that she had completely failed to acknowledge and respect her overriding professional responsibilities.”
The Committee considered that the offence was a serious one, taking into account the abuse of position and pre-meditated and dishonest conduct.
The Committee also took into account previous adverse findings against Mrs Grecko from 2011, which involved misconduct of a very similar nature, which meant that they could not accept her argument that she had learnt her lesson, and also meant that, in the Committee’s judgement, she presented a significant risk of further repeated errors of judgement and dishonest conduct.
Mr Morris added: “Further, the Committee considered that members of the public would be very concerned to learn that, having once been reprimanded for her previous dishonest conduct, Mrs Grecko had repeated her behaviour.
“It [the Committee] concluded that this rendered Mrs Grecko’s disgraceful conduct in a professional respect incompatible with continued registration and no lesser sanction than removal from the Register would be sufficient to protect the wider public interest in maintaining public confidence in the profession and declaring and upholding proper professional standards.”
Mrs Grecko now has 28 days from being informed of her removal from the Register to lodge an appeal.
www.rcvs.org.uk/disciplinary
Virbac has launched Sulfatrim, the first veterinary-licensed Trimethoprim and Sulfamethoxazole (TMPS) oral antibiotic for use in rabbits, pigeons and bearded dragons.
Kate Woolley MRCVS, Product Manager, said: "Until now, no similar veterinary-licensed product has been available for these species and, in an environment where vets are increasingly aware of the responsible use of antibiotics across all species, we are very happy to launch Sulfatrim, the first licensed TMPS for rabbits, pigeons and bearded dragons."
Sulfatrim is presented in a 30ml bottle with a dispensing cap and syringe.
In the trial, published in the Equine Veterinary Journal, synovitis was induced in the right intercarpal joint of 24 horses by intra‐articular injection of 0.5 ng lipopolysaccharide (LPS) of Escherichia coli. After intra‐articular challenge, the nutraceuticals resulted in significantly lower synovial fluid TP, TNCC and PGE 2 compared with placebo, leading the authors to conclude that: "The preventive administration of these nutraceuticals showed anti‐inflammatory effects in this validated synovitis model."
Dr Maarten Oosterlinck DVM, PhD, Dipl. ECVS, one of the authors of the study, said: "Nutraceuticals are often used in the management of osteoarthritis, which is a common cause of chronic lameness in horses but their 'curative' efficacy remains controversial and the quality of the relevant studies is generally low. We set out to evaluate ArtiTec in a well-designed and controlled study. Our research shows that ArtiTec significantly decreased joint inflammation and could be useful in preventing the onset of arthritis."
Cavalor also points to a further field trial of the product by vets in Belgium which showed that it improved lameness in 74% of cases.²
ArtiTec contains glucosamine, MSM, chondroitin, hyaluronic acid, blackcurrant extract, feverfew and pineapple, turmeric root and Boswellia Serrata.
Lieselot Hamerlinck, managing partner at Cavalor said: "Joint supplements account for 34% of the equine supplement market so we know how important these products are to horse owners. Cavalor ArtiTec is the result of an extensive research and development programme and its anti-inflammatory effect has been documented in both scientific studies and a field trial. It can also be used in combination with our other joint supplements, Arti Matrix and Arti Base."
For more information, contact Zebra Products on 01352 763350.
Elanco Animal Health has launched Vulketan, a POM-V sterile topical gel developed to encourage the healing of equine wounds.
Vulketan contains ketanserin - a serotonin-S2 antagonist.2 Elanco says that although serotonin is more widely known as a neurotransmitter in the brain, it is also found in platelets and released during platelet aggregation where it can have negative effects on wound healing.4, 7
Managing equine wounds is an everyday occurrence in equine practice1 and can be difficult and time-consuming, with many potential complications such as infection or the development of proud flesh which could delay healing or lead to reduced functionality. Repeated dressings can be a hassle for owners, and if used inappropriately can lead to their own complications.5
Elanco representative Kirsty Prudon said: "Vulketan gel is easy to use and is designed to be applied to undressed wounds, although it has been demonstrated that wounds may be dressed, if required, without affecting Vulketan's efficacy2,6.
Elanco also points to studies which it says demonstrate that Vulketan has been shown in client owned horses to be highly effective in preventing the formation of hypergranulation tissue and may facilitate the control of secondary infections.2,3,6. In addition, owners expressed satisfaction with Vulketan in over 90% of cases.6
Practising equine vet Linda Belton MRCVS said: "Vulketan is easy to use, well tolerated by horses and produces an excellent end cosmetic result and return to function. With the reduction in the need for dressings and proud flesh control Vulketan has proven to be an advantageous product which owners value."
Vulketan is suitable for use in all horses including pregnant and lactating mares. It is supplied in 75 gram tubes and should be applied twice daily.
For more information, contact your Elanco territory manager call Elanco on 01256 353131.
The study, Understanding How Dogs Age: Longitudinal Analysis of Markers of Inflammation, Immune Function, and Oxidative Stress, was published this week in the Journal of Gerontology: Biological Sciences1. It followed 80 dogs for over 10 years, from adulthood till end of life, measuring a number of parameters to track their aging process.
Findings included:
Mars says it is the largest prospective study to investigate aging in dogs and offers new insight into the ways in which we may be able to support dogs in their old age.
Janet Alexander, Senior Research Scientist at the Waltham Centre for Pet Nutrition and lead author of the study said: "We now know that dogs suffer from low level inflammation and cellular damage as they get older, similar to humans. The study identified multiple targets for potential therapeutic intervention to defend against or delay the impact of aging and the new insights can help us to provide more effective life stage support."
Mars has also released the results of its Aging Pets Ownership Survey2, conducted last month, which found that:
The Committee heard seven charges against Dr Elefterescu. The charges were:
In September 2015, in relation to a male cat called Kitty Brown, he failed to undertake an adequate examination prior to surgery and that he undertook an unnecessary laparotomy.
In February 2016, in relation to a male cat called Storm Page, he failed to undertake an adequate clinical examination prior to anaesthesia and made dishonest or misleading entries in the clinical records stating that he had undertaken a full clinical examination.
In February 2016, in relation to a male cat called Sampson Page, he failed to undertake an adequate clinical examination prior to anaesthesia and made dishonest or misleading entries to the effect that he had undertaken a full clinical examination.
In February 2016, in relation to Tibial Plateau Levelling Osteotomy (TPLO) surgery performed on a female Bichon Frise called Lucy Allen, he failed to undertake adequate examinations into the possibility of a cranial cruciate ligament rupture or failed to record the same; performed the TPLO surgery with insufficient clinical justification; performed the surgery inadequately; failed to take steps to rectify inadequate surgery having obtained post-operative radiographs; made dishonest/ misleading entries into clinical records; and, in a letter to the RCVS on 7 August 2016, made dishonest and misleading comments.
In February 2016, in relation to a male cat called Kipper Morley, he failed to take and record a sufficiently detailed history; failed to undertake an adequate clinical examination; that, having noted the possibility that Kipper might have anaemia, he failed to make arrangements for urgent investigations to be undertaken; that, having decided to administer intravenous fluids to Kipper, failed to make arrangements urgently; and failed to keep clear, accurate and detailed clinical records.
Between September 2015 and February 2016, he failed to keep clear, accurate clinical records in relation to seven cases.
In February 2016, in relation to a male cat named Chino Biggs, he failed to undertake adequate clinical examination and dishonestly made entries in the clinical records saying that he had undertaken aspects of an examination when he had not done so.
Having heard evidence from complainants, witnesses (including expert witnesses) and the respondent himself the Committee determined that the facts of all the charges were proven – with the exception of part of Charge 6 regarding his keeping inadequate clinical records in relation to a male cat called Dax Parham.
The Committee then went on to consider whether the proven charges, both individually and cumulatively, amounted to serious professional misconduct. In relation to the first and fifth charges the Committee found that, while Dr Elefterescu’s conduct fell below what was expected of a professional veterinary surgeon – they did not constitute serious professional conduct.
In relation to the parts of the second, third, fourth, sixth and seventh charges that were found proven, the Committee determined that each constituted serious professional misconduct.
In relation to these determinations, Ian Arundale, chairing the Committee and speaking on its behalf, said: "The respondent’s clinical failures… are very serious, amounting as they do to failures in the basics of animal care and resulting in suffering to the animal. They involve widespread breaches of the Code, including not only the obligation in relation to animal health and welfare… but also the specific obligations of the Code in relation to record keeping.
"In addition to his clinical and record keeping failures the respondent has been found to have acted dishonestly. This dishonesty would have impacted upon professional colleagues and any owner who viewed the records. It has the potential to undermine public confidence in the profession. The respondent was also dishonest in a letter written in August 2017 to his regulator."
In considering Dr Elefterescu’s sanction, the Committee took into account a number of aggravating and mitigating factors.
Aggravating factors included actual and risk of injury to animals, dishonesty, recklessness, breach of client trust, repeated misconduct and limited insight into his failings.
In mitigation the Committee considered that, at the time of the misconduct, the respondent was new to the UK, he had language difficulties which resulted in communication problems, that he was unfamiliar with UK veterinary computer systems and procedures, that he is of good character, that he has taken steps to avoid a repetition of his misconduct and that there have been no subsequent complaints since the dates of the matters in the charges.
However, the Committee found that, in light of the seriousness of the charges found against him, the only sufficient sanction was to direct the Registrar to remove Dr Elefterescu’s name from the Register.
Mr Arundale, commenting on the sanction, said: "The respondent’s misconduct involved very serious departures from the professional standards set out in the RCVS Code…. In particular, the unnecessary surgery (both the initial and revision) carried out on Lucy Allen constituted very serious harm to an animal. The Committee considers that the respondent’s lack of insight into his failings, and his wholly unjustified confidence in his abilities constitute an ongoing risk to animal welfare. In these circumstances, the Committee has determined that the only sanction which is appropriate and proportionate, in order to ensure the welfare of animals, the public interest and the reputation of the profession, is to direct the respondent’s removal from the Register."
Dr Elefterescu has 28 days in which he can lodge an appeal with the Privy Council regarding the Disciplinary Committee’s decision.
The study was part of the RVC’s VetCompass programme which include anonymised veterinary information from over eight million UK dogs. From this pool, a random sample of 22,333 dogs were followed for a year, identifying all health issues that were diagnosed during this time.
The study is one of the largest ever studies to explore the anonymised health records from veterinary surgeries and report on the most common disorders in dogs. The study also looked at whether the health of dogs varied by age, sex and whether the dogs were neutered.
The main findings were:
Dr Dan O’Neill, Senior Lecturer, Companion Animal Epidemiology at the RVC and lead author of the paper, said: "This study shows that it is really important for owners to develop strong habits of caring for their dog’s teeth, ears and weight, right from the time they first acquire a puppy.
"This study shows interesting and strong correlations between human and canine healthcare: the need for good dental and bodyweight maintenance. Given how closely the lives of humans and dogs are intertwined, this should be no surprise really; we often share the same food and exercise. Owners should work closely with their vet to plan appropriate dental and weight care programmes at each visit to their veterinary clinic.”
Hannah James, Health Research Manager at the Kennel Club, and co-author of the paper, said: "As dog owners, the key priority is keeping our pets healthy and happy, but it can be difficult to put into context the most common problems that affect our canine counterparts and which areas we need to pay particular attention to in order to maintain this. These findings help us establish these key areas, and where we as owners, vets and organisational bodies can work towards to improve the day-to-day life of our beloved companions."
O'Neill, D.G., James, H., Church, D.B., Brodbelt, D.C. and Pegram, C. (2021) 'Prevalence of commonly diagnosed disorders in UK dogs under primary veterinary care: results and applications', BMC Veterinary Research.
Photo: Uwe Gelle
George Philippus Hauptfleisch faced three charges in relation to allegations of clinical failings surrounding three patients:
The first charge surrounded the allegations that in 2018, Mr Hauptfleisch failed to provide appropriate and adequate care to Steel, a Cane Corso Mastiff, in that he performed surgery outside of his competence, failed to offer a reasonable range of treatment options as alternatives, failed to make adequate enquiries about the possibility of a referral to a specialist, failed to obtain informed consent to the surgery, and failed to maintain adequate clinical records.
The second charge, in relation to a German Shepherd, alleged that in 2019, Mr Hauptfleisch failed to provide appropriate and adequate care when he undertook surgery which was outside of his competence and failed to undertake the surgery to an adequate standard, failed to note sufficient details to show that informed consent for the surgery had been obtained, and failed to maintain adequate clinical records.
The third charge, in relation to a Retriever, alleged that Mr Hauptfleisch failed to provide appropriate and adequate care with regards to surgery he performed when it was outside of his competence, failed to undertake the surgery to an adequate standard, failed to note sufficient details that showed informed consent had been obtained, and failed to maintain adequate clinical records.
Prior to the hearing, Mr Hauptfleisch made an application to the Committee to dispose of the matter by way of adjournment for an indefinite period, against his undertakings to request the Registrar to remove him from the Register, and never to seek restoration to the Register.
In deciding whether to grant the application, the Committee took into account a number of factors.
These included the fact that Mr Hauptfliesch had, in December 2021, returned to South Africa, after a career of over 32 years in the UK, and now resides there permanently, the fact that he has no intention of moving back to the UK, and that he had not practised as a veterinary surgeon since the day he left.
He had also removed himself from the equivalent register in South Africa and the Committee noted that the RCVS would inform the South African Veterinary Council of the outcome of these proceedings.
The Committee also noted that there were no previous disciplinary findings against him, that Mr Hauptfleisch now spends the majority of his time undertaking charitable activities, including running a mentoring programme for young people, and, that he expressed deep regret for anything which he did or did not do which failed to protect the welfare of animals or caused upset to his clients and fellow members of the profession.
Mr Hauptfleisch also drew attention to the fact that the charges did not allege dishonesty and that the reputation of the profession would be upheld as Mr Hauptfleisch would no longer practise as a veterinary surgeon and would not return to practise.
Therefore, it would not be proportionate, nor in the public interest, for there to be a lengthy contested hearing resulting in substantial costs for both the RCVS and for Mr Hauptfleisch.
Hilary Lloyd, chairing the Committee and speaking on its behalf, said: “Taking into account the removal from the Register and the respondent’s undertaking never to apply for restoration, in conjunction with all of the circumstances, the Committee was satisfied that allowing the application would be sufficient to uphold the public interest, confidence in the profession and the RCVS as a regulator, and protect the welfare of animals.
“As a result of all the factors set out, and taking into account the nature of the charges which relate to the alleged inadequate standard of clinical practice, the Committee decided that this is not a case in which there were wider issues relevant to the profession at large, such as those which had public policy implications and which required full consideration at a hearing.
“The Committee was satisfied that neither the public interest nor the welfare of animals demands that there be a full hearing in this case.
“Taking into account proportionality and weighing in the balance all the circumstances of the case, the interests of justice, the public interest, the need to uphold proper standards of conduct and performance, and the need to protect the welfare of animals, the Committee decided to grant the respondent’s application.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings/
Virtual Recall's products include vaccination, neutering, appointment and healthcheck reminders, customer feedback, telemedicine and post operation surveys, and healthcare advice communications.
Jamie Brannan, Senior Vice President UK, Ireland and Nordics said: "This is an exciting opportunity for Zoetis to add a new solution for veterinarians with an innovative service that will support clinics in increasing their level of compliance, education and engagement at the pet owner level.
"As we expand our comprehensive offering across the continuum of care for veterinary clinics, Virtual Recall will enhance the level of pet owner services that can be offered to their pet owner customers in the UK, Australia and New Zealand.
“Our studies have shown that veterinary customers are keen to reduce administrative workload and find new ways to engage with pet owners. We believe that Virtual Recall will achieve that, helping to educate and improve pet owner compliance and adding financial benefits to the veterinary practice.”
Jamie Crittall, Co-founder, Virtual Recall said: “As a company we’ve always been restless – constantly looking at new ways and developing new technologies in which we can drive animal healthcare compliance. Zoetis’ thoroughly well-earned reputation for always putting their customers first – wanting them to thrive and be successful – combined with a commitment to enhance the lives of people and animals, is infectious. It is a very exciting new chapter for Virtual Recall and fellow co-founder Charlie Barton and I are thrilled to continue at the helm."